As pressure mounts on pharma R&D, demand rises for IP professionals by Nick Bellwood

10 March 2008

Life Science companies are feeling the pinch; productivity in R&D is dropping, there is increased pressure from regulators as well as pressure on price from payers, not to mention the generics threat. Companies are tightening their belts in terms of cost and ensuring that their current revenue streams are made secure. As the assets of companies in this sector are bound up in intellectual property, it is no surprise that the demand for professionals with IP experience, and in particular patent attorney qualification, is high.

The future of this sector may not sound particularly upbeat but pharmaceutical companies as well as their cousins in diagnostics, vaccines and medical devices are addressing these challenges on several fronts.

In pharmaceutical R&D, innovation is at the heart of discovering new drugs; drugs that are better than the competition or get to market faster than the competition. It is in this R&D space that patent attorneys really earn their salt.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight